Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.
Identifieur interne : 004C26 ( PubMed/Corpus ); précédent : 004C25; suivant : 004C27Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.
Auteurs : U B Muthane ; P. Satishchandra ; M N SubhashSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
- Acoustic Stimulation, Adolescent, Adult, Aged, Evoked Potentials, Auditory, Brain Stem, Evoked Potentials, Visual, Female, Homovanillic Acid (cerebrospinal fluid), Homovanillic Acid (metabolism), Humans, Hydroxyindoleacetic Acid (cerebrospinal fluid), Hydroxyindoleacetic Acid (metabolism), Male, Middle Aged, Parkinson Disease (cerebrospinal fluid), Parkinson Disease (diagnosis), Parkinson Disease (metabolism), Photic Stimulation.
- MESH :
- chemical , cerebrospinal fluid : Homovanillic Acid, Hydroxyindoleacetic Acid.
- chemical , metabolism : Homovanillic Acid, Hydroxyindoleacetic Acid.
- cerebrospinal fluid : Parkinson Disease.
- diagnosis : Parkinson Disease.
- metabolism : Parkinson Disease.
- Acoustic Stimulation, Adolescent, Adult, Aged, Evoked Potentials, Auditory, Brain Stem, Evoked Potentials, Visual, Female, Humans, Male, Middle Aged, Photic Stimulation.
Abstract
We studied visual (VEP) and brainstem auditory (BAEP) evoked potential changes in 23 patients with early onset Parkinson's disease (EOPD) to establish the nature of the changes as well as their relationship to dopaminergic (DA) and serotonergic (5-HT) disturbances, as determined by cerebrospinal fluid levels of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA). We also compared these parameters between the young onset (YOPD) and juvenile Parkinsonism (JP), the two subgroups of EOPD, to look for any possible differences between the two. In EOPD, the mean P100 latency of the VEP was significantly prolonged compared to controls (p < 0.001). However, within EOPD the evoked potential parameters were not significantly different between YOPD and the JP subgroups. P100 latency was abnormal in six patients (YOPD: 5, JP: 1) (26%). Six patients (YOPD: 3, JP:3) (26%) had abnormal BAEP. A significant negative correlation (r: -0.89, p < 1%) was observed between the P100 latency and CSF HVA levels. No correlation was observed between the BAEP interpeak latencies and either CSF HVA or 5-HIAA levels. This study suggests that VEP and BAEP abnormalities do occur in EOPD (in both YOPD and JP), and that the prolongation of P100 latency is secondary to DA deficiency as in PD. The cause of BAEP abnormalities is probably independent of DA and 5-HT disturbances. The only difference between EOPD and classical PD was the higher incidence of BAEP abnormalities in EOPD. There was no correlation between the VEP or BAEP changes to either the age at onset or duration of EOPD.
DOI: 10.1002/mds.870080316
PubMed: 7688076
Links to Exploration step
pubmed:7688076Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.</title>
<author><name sortKey="Muthane, U B" sort="Muthane, U B" uniqKey="Muthane U" first="U B" last="Muthane">U B Muthane</name>
<affiliation><nlm:affiliation>Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Satishchandra, P" sort="Satishchandra, P" uniqKey="Satishchandra P" first="P" last="Satishchandra">P. Satishchandra</name>
</author>
<author><name sortKey="Subhash, M N" sort="Subhash, M N" uniqKey="Subhash M" first="M N" last="Subhash">M N Subhash</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1993">1993</date>
<idno type="RBID">pubmed:7688076</idno>
<idno type="pmid">7688076</idno>
<idno type="doi">10.1002/mds.870080316</idno>
<idno type="wicri:Area/PubMed/Corpus">004C26</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.</title>
<author><name sortKey="Muthane, U B" sort="Muthane, U B" uniqKey="Muthane U" first="U B" last="Muthane">U B Muthane</name>
<affiliation><nlm:affiliation>Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Satishchandra, P" sort="Satishchandra, P" uniqKey="Satishchandra P" first="P" last="Satishchandra">P. Satishchandra</name>
</author>
<author><name sortKey="Subhash, M N" sort="Subhash, M N" uniqKey="Subhash M" first="M N" last="Subhash">M N Subhash</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1993" type="published">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acoustic Stimulation</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Evoked Potentials, Auditory, Brain Stem</term>
<term>Evoked Potentials, Visual</term>
<term>Female</term>
<term>Homovanillic Acid (cerebrospinal fluid)</term>
<term>Homovanillic Acid (metabolism)</term>
<term>Humans</term>
<term>Hydroxyindoleacetic Acid (cerebrospinal fluid)</term>
<term>Hydroxyindoleacetic Acid (metabolism)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (cerebrospinal fluid)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Photic Stimulation</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Homovanillic Acid</term>
<term>Hydroxyindoleacetic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Homovanillic Acid</term>
<term>Hydroxyindoleacetic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Acoustic Stimulation</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Evoked Potentials, Auditory, Brain Stem</term>
<term>Evoked Potentials, Visual</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Photic Stimulation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We studied visual (VEP) and brainstem auditory (BAEP) evoked potential changes in 23 patients with early onset Parkinson's disease (EOPD) to establish the nature of the changes as well as their relationship to dopaminergic (DA) and serotonergic (5-HT) disturbances, as determined by cerebrospinal fluid levels of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA). We also compared these parameters between the young onset (YOPD) and juvenile Parkinsonism (JP), the two subgroups of EOPD, to look for any possible differences between the two. In EOPD, the mean P100 latency of the VEP was significantly prolonged compared to controls (p < 0.001). However, within EOPD the evoked potential parameters were not significantly different between YOPD and the JP subgroups. P100 latency was abnormal in six patients (YOPD: 5, JP: 1) (26%). Six patients (YOPD: 3, JP:3) (26%) had abnormal BAEP. A significant negative correlation (r: -0.89, p < 1%) was observed between the P100 latency and CSF HVA levels. No correlation was observed between the BAEP interpeak latencies and either CSF HVA or 5-HIAA levels. This study suggests that VEP and BAEP abnormalities do occur in EOPD (in both YOPD and JP), and that the prolongation of P100 latency is secondary to DA deficiency as in PD. The cause of BAEP abnormalities is probably independent of DA and 5-HT disturbances. The only difference between EOPD and classical PD was the higher incidence of BAEP abnormalities in EOPD. There was no correlation between the VEP or BAEP changes to either the age at onset or duration of EOPD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7688076</PMID>
<DateCreated><Year>1993</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>1993</Year>
<Month>09</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>8</Volume>
<Issue>3</Issue>
<PubDate><Year>1993</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.</ArticleTitle>
<Pagination><MedlinePgn>344-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We studied visual (VEP) and brainstem auditory (BAEP) evoked potential changes in 23 patients with early onset Parkinson's disease (EOPD) to establish the nature of the changes as well as their relationship to dopaminergic (DA) and serotonergic (5-HT) disturbances, as determined by cerebrospinal fluid levels of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA). We also compared these parameters between the young onset (YOPD) and juvenile Parkinsonism (JP), the two subgroups of EOPD, to look for any possible differences between the two. In EOPD, the mean P100 latency of the VEP was significantly prolonged compared to controls (p < 0.001). However, within EOPD the evoked potential parameters were not significantly different between YOPD and the JP subgroups. P100 latency was abnormal in six patients (YOPD: 5, JP: 1) (26%). Six patients (YOPD: 3, JP:3) (26%) had abnormal BAEP. A significant negative correlation (r: -0.89, p < 1%) was observed between the P100 latency and CSF HVA levels. No correlation was observed between the BAEP interpeak latencies and either CSF HVA or 5-HIAA levels. This study suggests that VEP and BAEP abnormalities do occur in EOPD (in both YOPD and JP), and that the prolongation of P100 latency is secondary to DA deficiency as in PD. The cause of BAEP abnormalities is probably independent of DA and 5-HT disturbances. The only difference between EOPD and classical PD was the higher incidence of BAEP abnormalities in EOPD. There was no correlation between the VEP or BAEP changes to either the age at onset or duration of EOPD.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muthane</LastName>
<ForeName>U B</ForeName>
<Initials>UB</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Satishchandra</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Subhash</LastName>
<ForeName>M N</ForeName>
<Initials>MN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>54-16-0</RegistryNumber>
<NameOfSubstance UI="D006897">Hydroxyindoleacetic Acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>X77S6GMS36</RegistryNumber>
<NameOfSubstance UI="D006719">Homovanillic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000161">Acoustic Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016057">Evoked Potentials, Auditory, Brain Stem</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D005074">Evoked Potentials, Visual</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006719">Homovanillic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006897">Hydroxyindoleacetic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010775">Photic Stimulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year>
<Month>7</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1993</Year>
<Month>7</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1993</Year>
<Month>7</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">7688076</ArticleId>
<ArticleId IdType="doi">10.1002/mds.870080316</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004C26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:7688076 |texte= Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7688076" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |